# LLM call: summary

- Turn: 11
- Sequence: 7
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 732
- Completion tokens: 376
- Total tokens: 1221
- Cost (USD): 0.00015

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1582: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
By autumn 2029 US labs showed multi-day unsupervised engineering/research, with open replicas near prior frontier and AI infrastructure valuations collapsing — European datacentre/gigafactory expansions cancelled, US leased capacity repriced.

Chinese logistics humanoids arrived via Rotterdam/Hamburg amid frozen graduate hiring; Rotterdam, Lyon, Hamburg imposed moratorium pending safety/labour audits over unconfirmed injury and union inspection demands.

Brussels held EuroHPC fallback for hospitals/water/grid on European substitutes via bio-cyber mesh — degraded, with handwritten prescriptions and dosage distrust — plus mayoral audit scheme for case-by-case permits and wage-insurance, but inspectors few and moratorium held.

In spring a second US jump made the system a production tool with minimal oversight; replicas again neared the year-old frontier while assurance and evaluations expired. US-modelled tailored therapies reached Paris, Milan, Barcelona clinics on US-leased compute, then Washington tightened tiered export licensing — rationing, re-pricing, end-use conditions, halving two hospital clusters' inference by autumn.

Brussels launched Trusted Medical Access Programme reserving EuroHPC for diagnostics/dosage validation and EU-hosted procurement via bio-cyber mesh, using wage-insurance and mayoral audit sites as distribution. Entry-level transition guarantee and embodied audit pilots closed as small vs displacement. Wards stayed degraded — overrides, slow manufacturer data sharing, moratorium held; cures real but felt on leave.

CURRENT NARRATIVE:
### Certified, rationed, waiting
The certification drive began quickly. Joint Research Centre teams with ENISA and the AI Office took the new interpretability result — the first in years that worked on live hospital models rather than benchmarks — and applied it to dosage validators and triage support running on EuroHPC. A first list of pass-fail certificates was published in November. Clinicians in Paris and Milan said overrides fell where a certificate existed; where it did not, handwritten fallback continued.

The Trusted Medical Access Programme held the line it could. EuroHPC triage slots were reserved, joint procurement steered orders toward European-hosted deployment, and wage-insurance offices in Rotterdam, Lyon and Hamburg handed out appointments alongside benefits. But volume was the constraint. Washington's renewed licensing round cut allied hospital inference further, with re-pricing and end-use audits attached. Two research clusters ran at half allotment through autumn, queuing non-urgent validations for weeks.

Remissions from tailored therapies kept arriving, and families spoke of them gratefully — and bitterly. The treatment worked, the server was foreign, the permission could be repriced. Municipal papers called it medicine on leave.

Meanwhile freight insurers raised premiums after extended exercises around Taiwan. The Commission quietly tilted existing stockpiles — chips, medicines, inference reservations — toward hospitals, water and grid, without announcing a new instrument. Port operators noted the signal: prepare, but do not alarm.

Inspectors remained few, manufacturers still slow to share machine data, and the moratorium on new logistics machines stayed in place. Assurance improved from zero, but open replicas now matched the frontier of a year ago, and reviewers warned the audit window would close again within months.
```

## Raw response

```
By autumn 2029 US labs showed multi-day unsupervised engineering with open replicas near prior frontier and AI infrastructure valuations collapsing — European datacentre expansions cancelled, US leased capacity repriced.

Chinese logistics humanoids arrived via Rotterdam/Hamburg amid frozen graduate hiring; Rotterdam, Lyon, Hamburg imposed moratorium pending safety/labour audits over injury reports and union demands.

Brussels held EuroHPC fallback for hospitals/water/grid on European substitutes via bio-cyber mesh — degraded, with handwritten prescriptions and dosage distrust — plus mayoral audits, wage-insurance, and entry-level guarantee/embodied pilots too small vs displacement.

A second US jump made AI a production tool with minimal oversight; replicas neared year-old frontier, assurance expired. US-modelled tailored therapies reached Paris, Milan, Barcelona on US-leased compute, then Washington tightened tiered export licensing — rationing, re-pricing, end-use conditions, halving two hospital clusters' inference.

Brussels launched Trusted Medical Access Programme reserving EuroHPC for diagnostics/dosage validation and EU-hosted procurement via wage-insurance/mayoral sites. JRC-ENISA-AI Office applied new live-model interpretability to publish pass-fail certificates in November, cutting overrides where certified; uncertified wards stayed on fallback.

Renewed US licensing cut allied hospital inference further with audits, queuing validations for weeks. Remissions continued but felt as medicine on leave — effective, foreign-hosted, repricable. Commission quietly tilted stockpiles — chips, medicines, inference — to hospitals/water/grid amid Taiwan-related freight premium rises. Moratorium held, inspectors few, data sharing slow; audit window warned to close within months as open replicas matched year-ago frontier.

```
